BRPI0909630B8 - composição em suspensão aquosa particularmente adequada para injeção dentro do olho - Google Patents

composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Info

Publication number
BRPI0909630B8
BRPI0909630B8 BRPI0909630A BRPI0909630A BRPI0909630B8 BR PI0909630 B8 BRPI0909630 B8 BR PI0909630B8 BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 A BRPI0909630 A BR PI0909630A BR PI0909630 B8 BRPI0909630 B8 BR PI0909630B8
Authority
BR
Brazil
Prior art keywords
particularly suitable
injection
eye
aqueous suspension
suspension composition
Prior art date
Application number
BRPI0909630A
Other languages
English (en)
Inventor
P Kabra Bhagwati
Sarkar Ruma
Original Assignee
Alcon Inc
Alcon Res Llc
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc, Alcon Res Llc, Alcon Res Ltd filed Critical Alcon Inc
Publication of BRPI0909630A2 publication Critical patent/BRPI0909630A2/pt
Publication of BRPI0909630B1 publication Critical patent/BRPI0909630B1/pt
Publication of BRPI0909630B8 publication Critical patent/BRPI0909630B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Abstract

composição em suspensão aquosa particularmente adequada para injeção dentro do olho e usos da referida composição. a presente invenção refere-se a composição em suspensão de triancinolona acetonidas. as composições em suspensão possuem uma viscosidade relativamente baixa e são fáceis de extrusar através de uma agulha de calibre 27 ou 30, mas são altamente floculadas e facilmente dispersas novamente. as composições são particularmente adequadas para injeção intravitreal.
BRPI0909630A 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho BRPI0909630B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3545908P 2008-03-11 2008-03-11
US61/035,459 2008-03-11
PCT/US2009/036652 WO2009114521A1 (en) 2008-03-11 2009-03-10 Low viscosity, highly flocculated triamcinolone acetonide suspensions for intravitreal injection

Publications (3)

Publication Number Publication Date
BRPI0909630A2 BRPI0909630A2 (pt) 2015-09-22
BRPI0909630B1 BRPI0909630B1 (pt) 2019-03-26
BRPI0909630B8 true BRPI0909630B8 (pt) 2021-05-25

Family

ID=40548758

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0909630A BRPI0909630B8 (pt) 2008-03-11 2009-03-10 composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Country Status (22)

Country Link
US (3) US8128960B2 (pt)
EP (1) EP2262506B1 (pt)
JP (1) JP5581227B2 (pt)
KR (1) KR101555293B1 (pt)
CN (1) CN101959519B (pt)
AR (1) AR070824A1 (pt)
AU (1) AU2009223649B2 (pt)
BR (1) BRPI0909630B8 (pt)
CA (1) CA2717605C (pt)
CL (1) CL2009000573A1 (pt)
DK (1) DK2262506T3 (pt)
ES (1) ES2471122T3 (pt)
HK (1) HK1146464A1 (pt)
MX (1) MX2010009974A (pt)
PL (1) PL2262506T3 (pt)
PT (1) PT2262506E (pt)
RU (1) RU2481842C2 (pt)
SI (1) SI2262506T1 (pt)
TW (1) TWI468165B (pt)
UY (1) UY31699A1 (pt)
WO (1) WO2009114521A1 (pt)
ZA (1) ZA201005839B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070202186A1 (en) 2006-02-22 2007-08-30 Iscience Interventional Corporation Apparatus and formulations for suprachoroidal drug delivery
BRPI0909630B8 (pt) * 2008-03-11 2021-05-25 Alcon Inc composição em suspensão aquosa particularmente adequada para injeção dentro do olho
AU2009330517A1 (en) * 2008-12-22 2010-07-01 Alcon Research, Ltd. Compositions of topical ocular solutions to deliver effective concentrations of active agent to the posterior segment of the eye
BR112013009205A2 (pt) 2010-10-15 2016-07-26 Iscience Interventional Corp dispositivo para colocação na esclera de um olho, método para acessar o espaço supracoroidal de um olho, para acessar o espaço subretinal de um olho e para colocar um orifício dentro de um trato escleral em um olho.
CN102008488B (zh) * 2010-11-24 2012-10-10 广州固志医药科技有限公司 一种曲安奈德眼用制剂及其制备方法
AR090775A1 (es) * 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
EA034963B1 (ru) * 2012-11-08 2020-04-13 Клиасайд Байомедикал, Инк. Способ лечения расстройства заднего сегмента глаза
BR112015027762A2 (pt) 2013-05-03 2017-08-29 Clearside Biomedical Inc Aparelho e métodos para injeção ocular
US10188550B2 (en) 2013-06-03 2019-01-29 Clearside Biomedical, Inc. Apparatus and methods for drug delivery using multiple reservoirs
CA2952958A1 (en) 2014-06-20 2015-12-23 Clearside Biomedical, Inc. Variable diameter cannula and methods for controlling insertion depth for medicament delivery
US9694145B1 (en) 2016-03-29 2017-07-04 Joseph Onorato Auto-injector systems and method for delivering cyst medication on demand
WO2017192565A1 (en) 2016-05-02 2017-11-09 Clearside Biomedical, Inc. Systems and methods for ocular drug delivery
CN110177527B (zh) 2016-08-12 2022-02-01 科尼尔赛德生物医学公司 用于调节药剂递送用针的插入深度的装置和方法
WO2019136512A1 (en) * 2018-01-10 2019-07-18 Eye Co Pty Ltd Medical device and pharmaceutical composition for treatment of an eye disease or condition
USD893715S1 (en) 2018-11-06 2020-08-18 Joseph Onorato Measurement guide for a cyst, lesion or skin disorder
US20220211618A1 (en) * 2019-04-16 2022-07-07 Clearside Biomedical, Inc. Injectable triamcinolone formulations
US10814001B1 (en) 2019-05-06 2020-10-27 Rvl Pharmaceuticals, Inc. Oxymetazoline compositions
CN114010593A (zh) * 2021-11-23 2022-02-08 莱默(北京)药业科技有限公司 一种曲安奈德混悬注射液及制备方法

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3962430A (en) * 1974-08-07 1976-06-08 Merck & Co., Inc. Sterilization of solid non-electrolyte medicinal agents employing sodium chloride
US4370325A (en) * 1979-03-30 1983-01-25 Dermik Laboratories Pharmaceutical compositions and method of treatment
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US5164190A (en) * 1990-12-11 1992-11-17 Theratech, Inc. Subsaturated transdermal drug delivery device exhibiting enhanced drug flux
US5770589A (en) 1993-07-27 1998-06-23 The University Of Sydney Treatment of macular degeneration
AU4472396A (en) 1994-12-30 1996-07-24 American Home Products Corporation Clear non-alcoholic hydrocortisone solutions
KR20010071827A (ko) 1998-07-10 2001-07-31 앤더슨 데릭 제이. 반점성망막 퇴행에서 신혈관 신생의 예방치료
AR026073A1 (es) 1999-10-20 2002-12-26 Nycomed Gmbh Composicion farmaceutica acuosa que contiene ciclesonida
AUPQ496500A0 (en) 2000-01-06 2000-02-03 University Of Sydney, The Kit
US6395294B1 (en) 2000-01-13 2002-05-28 Gholam A. Peyman Method of visualization of the vitreous during vitrectomy
US6656505B2 (en) * 2000-07-21 2003-12-02 Alpharma Uspd Inc. Method for forming an aqueous flocculated suspension
AU2001278779A1 (en) * 2000-08-25 2002-03-04 Senju Pharmaceutical Co. Ltd. Aqueous suspension preparations
DE60233414D1 (de) * 2001-07-09 2009-10-01 Combinatorx Inc Kombinationen für die behandlung entzündlicher erkrankungen
US20030129242A1 (en) 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
US20040171598A1 (en) 2003-02-20 2004-09-02 Bingaman David P. Use of steroids to treat persons suffering from ocular disorders
US20040186084A1 (en) 2003-03-21 2004-09-23 Akorn, Inc. Triamcinolone formulations and methods for their preparation and use
US20050065137A1 (en) * 2003-09-23 2005-03-24 Alcon, Inc. Triamcinolone acetonide and anecortave acetate formulations for injection
US20070224278A1 (en) 2003-11-12 2007-09-27 Lyons Robert T Low immunogenicity corticosteroid compositions
US20060141049A1 (en) 2003-11-12 2006-06-29 Allergan, Inc. Triamcinolone compositions for intravitreal administration to treat ocular conditions
US20050101582A1 (en) 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
EP1703894A1 (en) * 2003-12-23 2006-09-27 ALZA Corporation Methods and dosage forms for increasing solubility of drug compositions for controlled delivery
DE602005011928D1 (de) 2004-01-20 2009-02-05 Allergan Inc Zusammensetzungen für die lokalisierte therapie des auges, vorzugsweise enthaltend triamcinolon-acetonid und hyaluronsäure
US20050244469A1 (en) * 2004-04-30 2005-11-03 Allergan, Inc. Extended therapeutic effect ocular implant treatments
US20070225727A1 (en) 2004-05-31 2007-09-27 Keiichi Matsuhisa Transparent Tissue-Visualizng Preparation
US20060089590A1 (en) 2004-10-27 2006-04-27 John Higuchi Methods and devices for sustained in-vivo release of an active agent
US20080008762A1 (en) 2004-11-17 2008-01-10 Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services Steroid Formulation And Methods Of Treatment Using Same
CA2598095A1 (en) * 2005-02-18 2009-08-24 Santen Pharmaceutical Co., Ltd. Method of relieving or avoiding side effect of steroid
US7893040B2 (en) * 2005-07-22 2011-02-22 Oculis Ehf Cyclodextrin nanotechnology for ophthalmic drug delivery
ITRM20050547A1 (it) 2005-11-04 2007-05-05 Sooft Italia S R L Gel oftalmico composto da triamcinolone acetonide e da un polimero poliacrilico.
BRPI0909630B8 (pt) * 2008-03-11 2021-05-25 Alcon Inc composição em suspensão aquosa particularmente adequada para injeção dentro do olho

Also Published As

Publication number Publication date
DK2262506T3 (da) 2014-06-10
ZA201005839B (en) 2011-10-26
CA2717605A1 (en) 2009-09-17
TW200940071A (en) 2009-10-01
CL2009000573A1 (es) 2010-01-04
US20090233890A1 (en) 2009-09-17
JP5581227B2 (ja) 2014-08-27
MX2010009974A (es) 2010-09-30
BRPI0909630B1 (pt) 2019-03-26
CN101959519B (zh) 2013-03-20
KR101555293B1 (ko) 2015-10-06
EP2262506B1 (en) 2014-05-07
CN101959519A (zh) 2011-01-26
RU2010141542A (ru) 2012-04-20
CA2717605C (en) 2012-05-15
AU2009223649B2 (en) 2013-08-29
SI2262506T1 (sl) 2014-07-31
ES2471122T3 (es) 2014-06-25
HK1146464A1 (en) 2011-06-10
US8211880B2 (en) 2012-07-03
US20120116216A1 (en) 2012-05-10
AU2009223649A1 (en) 2009-09-17
BRPI0909630A2 (pt) 2015-09-22
US20120115829A1 (en) 2012-05-10
PL2262506T3 (pl) 2014-09-30
RU2481842C2 (ru) 2013-05-20
AR070824A1 (es) 2010-05-05
US8128960B2 (en) 2012-03-06
KR20100127267A (ko) 2010-12-03
TWI468165B (zh) 2015-01-11
PT2262506E (pt) 2014-06-24
JP2011513492A (ja) 2011-04-28
UY31699A1 (es) 2009-05-29
EP2262506A1 (en) 2010-12-22
WO2009114521A1 (en) 2009-09-17

Similar Documents

Publication Publication Date Title
BRPI0909630B8 (pt) composição em suspensão aquosa particularmente adequada para injeção dentro do olho
BR112014003903A2 (pt) composições dentais que compreendem agentes de adição fragmentação
EA201290482A1 (ru) Стабильные составы для лиофилизации терапевтических частиц
BR112014011841A2 (pt) material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos
MX2014014902A (es) Composiciones que comprenden apomorfina y acidos organicos y usos de las mismas.
BRPI1105992B8 (pt) Composição para limpeza da pele
WO2010000877A3 (en) Formulation with irritation reducing action comprising bisabolol and [6]-paradol
GB201020193D0 (en) Glucan compositions
BR112012028291A2 (pt) composições farmacêuticas e métodos para sua produção
BR112014029286A2 (pt) composição cosmética sólida, processo para sua produção, produto e método cosmético
BRPI0911907B8 (pt) processo para produzir uma composição contendo triptofano e composição proteica contendo triptofano
BR112015009989A2 (pt) estabilizante para a hialuronidase e formulação líquida que compreende hialuronidase
BR112015017246A2 (pt) formulação farmacêutica que compreende um corticosteroide insolúvel e um corticosteroide solúvel
BR112012028893A2 (pt) composições imunoestimuladoras e de vacina
EA201891754A1 (ru) Композиции гиалуроновой кислоты, включающие мепивакаин
IN2015DN01489A (pt)
MY156963A (en) Ethanol compositions
BR112015001728B8 (pt) composições de condicionador
BR112018012952A2 (pt) composições para higiene pessoal
MY192813A (en) Aqueous formulation comprising paracetamol and ibuprofen
BR112016006963A2 (pt) composição farmacêutica
BR112017026904A2 (pt) formulações farmacêuticas injetáveis de lefamulina
WO2014097258A3 (en) Aqueous cosmetic composition comprising alkylcellulose
MX2010003914A (es) Nuevas composiciones a base de taxoides.
MX339361B (es) Derivados de alternano.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/03/2019, OBSERVADAS AS CONDICOES LEGAIS

B25A Requested transfer of rights approved

Owner name: ALCON RESEARCH, LLC (US)

B25A Requested transfer of rights approved

Owner name: ALCON INC. (CH)

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)